NEO####

ORAL, POTENT, DUAL INHIBITOR OF BET & CBP/P300

Bromodomain inhibitor against cancer

Indications

Acute leukemia, breast cancer, glioblastoma, lung cancer, lymphoma, melanoma, mesothelioma, neuroblastoma, ovarian cancer, pancreatic cancer, prostate cancer

Mode Of Action

Dual inhibitor of BET and CBP/P300

Main Advantages

  • Selective for bromodomain family of targets
  • Bromodomain (BRD) compounds inhibit epigenetic reader proteins that modulate transcription of genes associated with disease states
  • Additional activity at CREBBP and EP300 synergizes with BET activity providing enhanced efficacy resulting in a larger therapeutic window
  • NEO#### exhibits both cytotoxic and immuno-oncological properties

Collaborators



Epigenetix Inc., Florida, USA


Testimonials

How NEO#### Works

Bromodomains (BRDs) are key modulators of epigenetic control – this control is abnormal in some cancers. BRD4 inhibitors can treat cancer by restoring epigenetic control.
Much support has been accumulating for BRDs as cancer targets. NEO#### demonstrates a broad spectrum of in-vitro activity against a variety of cancer types and will be explored in priority indications which will be chosen based on data from our extensive pre-clinical collaborations.
Synergistically inhibiting both BRD4 and CBP/P300 may explain the observed enhanced efficacy as compared to other compounds in development.

Safety has been demonstrated in rodents, dogs and non-human primates in several non-GLP studies. In vitro and in vivo studies have shown at least 10-fold better cell membrane penetration and anti-tumor potency than other inhibitors in development while maintening a good safety profile.

Compounds were identified from 4 different chemical series with distinct scaffolds. Due to its superior in-vivo efficacy NEO#### was the selected lead candidate.

For more information

Bill Brown

Project Director

514-367-1212 bbrown@neomed.ca
© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia